Acyclovir News and Research

RSS
Acyclovir is a synthetic analog of the purine nucleoside, guanosine, with potent antiviral activity against herpes simplex viruses type 1 and 2, varicella-zoster virus and other viruses. After conversion in vivo to the active metabolite acyclovir triphosphate, acyclovir competitively inhibits viral DNA polymerase, incorporates into and terminates the growing viral DNA chain, and inactivates viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the thymidine kinase of HSV.
BioAlliance Pharma's LIP phase III pivotal study provides positive preliminary results

BioAlliance Pharma's LIP phase III pivotal study provides positive preliminary results

Nanoviricides anti-herpes drug candidate reduces viral load by 99.99%

Nanoviricides anti-herpes drug candidate reduces viral load by 99.99%

New research helps explain why treated genital herpes sores boost risk of HIV infection

New research helps explain why treated genital herpes sores boost risk of HIV infection

US FDA approves Lipsovir for cold sores

US FDA approves Lipsovir for cold sores

Herpes drug Acyclovir does not reduce risk of HIV transmission, does slow HIV progression, study says

Herpes drug Acyclovir does not reduce risk of HIV transmission, does slow HIV progression, study says

Anti-herpes drug acyclovir inhibits HIV replication, but with a price

Anti-herpes drug acyclovir inhibits HIV replication, but with a price

Herpes drug Acyclovir could help control HIV

Herpes drug Acyclovir could help control HIV

Herpes virus changes anti-herpes drug acyclovir to form that hinders AIDS virus

Herpes virus changes anti-herpes drug acyclovir to form that hinders AIDS virus

New understanding of how herpes simplex virus 1 hides during inactive phase

New understanding of how herpes simplex virus 1 hides during inactive phase

BioAlliance Pharma announces preliminary results from U.S. phase III trial for Loramyc

BioAlliance Pharma announces preliminary results from U.S. phase III trial for Loramyc

New therapeutic options for newly diagnosed multiple myeloma patients

New therapeutic options for newly diagnosed multiple myeloma patients

Immtech and BioAlliance sign agreement on Pafuramidine for African sleeping sickness

Immtech and BioAlliance sign agreement on Pafuramidine for African sleeping sickness

New treatment a cure for Bell's Palsy

New treatment a cure for Bell's Palsy

Long-term herpes treatment may reduce HIV infectivity

Long-term herpes treatment may reduce HIV infectivity

Herpes treatment could slow HIV progression in people living with both viruses

Herpes treatment could slow HIV progression in people living with both viruses

Treatment with intravenous and oral antiviral medications may help relieve nerve pain related to shingles

Treatment with intravenous and oral antiviral medications may help relieve nerve pain related to shingles

Acyclovir use uncertain in children with chickenpox

Acyclovir use uncertain in children with chickenpox

THC in marijuana may block the spread of forms of cancer causing herpes viruses

THC in marijuana may block the spread of forms of cancer causing herpes viruses

Chickenpox (Varicella) vaccine has saved the U.S. hundreds of millions of dollars since its introduction

Chickenpox (Varicella) vaccine has saved the U.S. hundreds of millions of dollars since its introduction

Third Annual Encephalitis Conference

Third Annual Encephalitis Conference

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.